News | November 14, 2024
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
